# Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

> **NCT05869201** · PHASE2,PHASE3 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 450 (actual)

## Conditions studied

- Influenza
- Influenza, Human
- Influenza Viral Infections
- Vaccine Reaction
- Vaccination; Infection

## Interventions

- **BIOLOGICAL:** Influenza vaccine [inactivated]
- **BIOLOGICAL:** Influenza vaccine [inactivated]
- **BIOLOGICAL:** Influenza vaccine [inactivated]

## Key facts

- **NCT ID:** NCT05869201
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-06
- **Primary completion:** 2020-12-08
- **Final completion:** 2020-12-08
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2023-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869201, "Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05869201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*